How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

129,191 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Demulen 1/35

Demulen 1/35 Demulen 1/35 Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Demulen 1/35 Demulen 1/35 Aka: Demulen 1/35 , Zovia 1/35 (...) , Kelnor II. Preparations (Ethynodiol Diacetate / Ethinyl Estradiol) Demulen 1.0 / 35 Zovia 1/35 Kelnor III. Components 1.0 mg (see preparation above) 35 ug IV. Effects Relative : 1.4 (high) : 19 (low) : 0.21 (moderate) V. Pill associated problems Indications to switch to (lower androgen) Increased Appetite (lower ) provoked (lower ) Heavy (more or less ) Moodiness (less or more ) Weight gain (less or more ) Indications to switch to s (lower ) Indications to switch to Tenderness or engorgement (lower

2018 FP Notebook

2. Weekly Bulletin on Outbreak and other Emergencies: Week 35: 26 August - 1 September 2017

Weekly Bulletin on Outbreak and other Emergencies: Week 35: 26 August - 1 September 2017 Weekly Bulletin on Outbreaks and other Emergencies: Week 35: 26 August - 1 September 2017 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Weekly Bulletin on Outbreaks and other Emergencies: Week 35: 26 August - 1 September 2017 View/ Open View Statistics Altmetrics Share Other Titles (...) Health Emergency Information and Risk Assessment Citation World Health Organization. Regional Office for Africa, Health Emergencies Programme . (‎2017)‎. Weekly Bulletin on Outbreaks and other Emergencies: Week 35: 26 August - 1 September 2017. Weekly Bulletin on Outbreaks and other Emergencies, 1 - 12. World Health Organization. Regional Office for Africa. Journal Weekly Bulletin on Outbreaks and other Emergencies1 - 12 Description 12 p. Collections Language English Metadata Related items Showing

2017 WHO

3. Optimizing whole blood storage: hemostatic function of 35-day stored product in CPD, CP2D, and CPDA-1 anticoagulants. (PubMed)

Optimizing whole blood storage: hemostatic function of 35-day stored product in CPD, CP2D, and CPDA-1 anticoagulants. Transitioning from whole blood (WB) to components developed from efforts to maximize donor yield. Components are advantageous for specific derangements, but treating hemorrhage with components requires significantly more volume to provide similar effects to WB. Because storage lesion and waste remain problematic, this study examined hemostatic function of refrigerated WB stored (...) for 35 days in anticoagulants citrate-phosphate-dextrose-adenosine (CPDA-1), citrate-phosphate-dextrose (CPD), or citrate-phosphate-double dextrose (CP2D).Refrigerated WB units from healthy donors were sampled over 35 days. Global hemostatic parameters were measured by thromboelastometry, thrombogram, platelet aggregometry, and platelet adhesion to collagen under shear conditions. The effects of transfusion filtration and mixing 35-day stored product with fresh WB were evaluated.Countable platelets

Full Text available with Trip Pro

2019 Transfusion

4. Bariatric surgery for Type 2 Diabetes and a body mass index below 35

Bariatric surgery for Type 2 Diabetes and a body mass index below 35 Bariatric surgery for Type 2 Diabetes and a body mass index below 35 - Health Technology Assessment - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Bariatric surgery for Type 2 Diabetes and a body mass index below 35 (...) - Health Technology Assessment Have you found an error? Order Download: Key message We have conducted a health technology assessment (HTA) that addresses efficacy, safety and a health-economic evaluation of bariatric surgery for patients with type 2 diabetes and a BMI below 35 compared to standard treatment. We included four randomized and six non-randomized controlled studies as well as one large registry study with no control group. After two-years of follow-up we found that: On average, 44

2018 Norwegian Institute of Public Health

5. Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets (PubMed)

Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets During the progression of epithelial cancer, the cells may lose epithelial markers and gain mesenchymal phenotype via Epithelial-Mesenchymal Transition (EMT). Such transformation of epithelial cancer cells to mesenchymal-like characteristic benefits plasticity and supports their ability to migrate. The aim of this study (...) cancer cells with CA and with Met, suppressed the motility of cells and the effect depended on a particular cell line. Both compounds regulated the EMT process in C4-I and HTB-35 cells by interfering with different molecular targets. In TGF-β1-stimulated C4-I cells, CA suppressed the expression of mesenchymal transcription factor SNAI1 which resulted in enhanced expression of epithelial markers E-cadherin, Occludin and Claudin. Additionally, CA blocked MMP-9 and upregulated TIMP-1 expression

Full Text available with Trip Pro

2018 International journal of molecular sciences

6. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor‐β type I receptor/apoptosis signal‐regulating kinase 1/mitogen‐activated protein kinase signaling axis (PubMed)

Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor‐β type I receptor/apoptosis signal‐regulating kinase 1/mitogen‐activated protein kinase signaling axis Solute carrier family members control essential physiological functions and are tightly linked to human diseases. Solute carrier family 35 member F2 (SLC35F2) is aberrantly activated in several malignancies. However, the biological function (...) and invasion and induced G1 phase arrest. In contrast, ectopic expression of SLC35F2 brought about aggressive malignant phenotypes of PTC cells. Moreover, SLC35F2 expedited the proliferation and migration of PTC cells by targeting transforming growth factor-β type I receptor (TGFBR1) and phosphorylation of apoptosis signal-regulating kinase 1 (p-ASK-1), thereby activating the mitogen-activated protein kinase signaling pathway. The malignant behaviors induced by overexpression of SLC35F2 could be abrogated

Full Text available with Trip Pro

2018 Cancer science

7. Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control (PubMed)

Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control HLA-B*35 is an HLA allele associated with rapid progression to AIDS. However, a mechanism underlying the detrimental effect of HLA-B*35 on disease outcome remains unknown. Recent studies demonstrated that most prevalent subtype HLA-B*35:01 is a detrimental allele in HIV-1 clade B-infected individuals. We here investigated the effect of mutations within the epitopes on HLA-B*35:01 (...) -restricted CD8+ T cells having abilities to suppress HIV-1 replication.We analyzed 16 HLA-B*35:01-restricted epitope-specific T cells in 63 HIV-1 clade B-infected Japanese B*35:01+ individuals and identified HLA-B*35:01-restricted CD8+ T cells having abilities to suppress HIV-1 replication. We further analyzed the effect of HLA-associated mutations on the ability of these T cells.The breadth of T cell responses to 4 epitopes was inversely associated with plasma viral load (pVL). However, the accumulation

Full Text available with Trip Pro

2018 EBioMedicine

8. Demulen 1/35

Demulen 1/35 Demulen 1/35 Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Demulen 1/35 Demulen 1/35 Aka: Demulen 1/35 , Zovia 1/35 (...) , Kelnor II. Preparations (Ethynodiol Diacetate / Ethinyl Estradiol) Demulen 1.0 / 35 Zovia 1/35 Kelnor III. Components 1.0 mg (see preparation above) 35 ug IV. Effects Relative : 1.4 (high) : 19 (low) : 0.21 (moderate) V. Pill associated problems Indications to switch to (lower androgen) Increased Appetite (lower ) provoked (lower ) Heavy (more or less ) Moodiness (less or more ) Weight gain (less or more ) Indications to switch to s (lower ) Indications to switch to Tenderness or engorgement (lower

2015 FP Notebook

9. Guidelines for Management of Jaundice in the Breastfeeding Infant 35 Weeks or More of Gestation

Guidelines for Management of Jaundice in the Breastfeeding Infant 35 Weeks or More of Gestation ABM Protocol ABM Clinical Protocol #22: Guidelines for Management of Jaundice in the Breastfeeding Infant 35 Weeks or More of Gestation—Revised 2017 Valerie J. Flaherman, 1 M. Jeffrey Maisels, 2 and the Academy of Breastfeeding Medicine A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols free from commercial interest or in?uence for managing common medical (...) and ?uid intake and stimulates breast milk production. In normal adults, the absence of caloric intake, even for as brief a period as 24 hours and with good hydration, results in a small increase in unconjugated hyperbilirubinemia of about 17–34lmol/L (1–2 mg/dL), 32–34 an effect due to an increase in the enterohepatic circulation of bilirubin. 35 Si- milarly, in newborns, breastfeeding dif?culties or a delay in the onset of secretory activation (lactogenesis ll) 36 may result in lower caloric intake

2017 Academy of Breastfeeding Medicine

10. Increased Interleukin-35 Levels in Patients With Type 1 Diabetes With Remaining C-Peptide. (PubMed)

Increased Interleukin-35 Levels in Patients With Type 1 Diabetes With Remaining C-Peptide. Many patients with long-standing type 1 diabetes have remaining functional β-cells. This study investigated immunological differences between patients with or without measurable remaining endogenous insulin production after ≥10 years duration of disease.Patients (n = 113; ≥18 years of age) with type 1 diabetes and with disease duration of ≥10 years were recruited at Uppsala University Hospital. Residual β (...) with remaining endogenous β-cell function after >10 years duration of type 1 diabetes differ immunologically from other patients with long-standing type 1 diabetes. In particular, they have a much higher IL-35 production.© 2017 by the American Diabetes Association.

Full Text available with Trip Pro

2017 Diabetes Care

11. The mechanism of killing by the proline-rich peptide Bac7(1-35) against clinical strains of Pseudomonas aeruginosa differs from that showed against other Gram-negative bacteria. (PubMed)

The mechanism of killing by the proline-rich peptide Bac7(1-35) against clinical strains of Pseudomonas aeruginosa differs from that showed against other Gram-negative bacteria. Pseudomonas aeruginosa infections represent a serious threat to worldwide health. Proline-rich antimicrobial peptides (PR-AMPs), a particular group of peptide antibiotics, have demonstrated in vitro activity against P. aeruginosa strains. Here we show that the mammalian PR-AMP Bac7(1-35) is active against some multidrug (...) internalized by means of the transporter SbmA without membranolytic effects. The heterologous expression of SbmA in PAO1 cells enhanced the internalization of Bac7(1-35) into the cytoplasm, making the bacteria more susceptible to the peptide but at the same time more resistant to the membrane lysis, similarly to what occurs in E. coli The results evidenced a new mechanism of action for PR-AMPs and indicate that Bac7 has multiple and variable modes of action that depend on the characteristics

Full Text available with Trip Pro

2017 Antimicrobial Agents and Chemotherapy

12. Bariatric surgery in 1119 patients with preoperative body mass index<35 (kg/m(2)): results at 1 year. (PubMed)

Bariatric surgery in 1119 patients with preoperative body mass index<35 (kg/m(2)): results at 1 year. The use of body mass index (BMI) as the only criterion to indicate bariatric surgery is currently under discussion. There is growing evidence that supports bariatric surgery in carefully selected patients with lower BMI.To report our experience in bariatric surgery in>1000 patients with BMI<35 kg/m(2) and their results at 1 year.University hospital (censored).A retrospective analysis (...) was performed in patients who underwent laparoscopic Roux-en-Y gastric bypass (LRYGB) or sleeve gastrectomy (SG) with preoperative BMI<35 kg/m(2) from January 2008 to December 2011. Demographic and anthropometric data, preoperative co-morbidities, and perioperative variables were retrieved. Weight loss and co-morbidities progression were analyzed 1 year after surgery and compared among procedures. A P value<.05 was considered significant.We identified 1119 patients: mean age 38.8±11.4, 951 (85%) women

2017 Surgery for Obesity and Related Diseases

13. DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury (PubMed)

DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury Traumatic brain injury (TBI) results in severe neurological impairments without effective treatments. Inflammation appears to be an important contributor to key pathogenic events such as secondary brain injury following TBI and therefore serves as a promising target for novel therapies. We have recently demonstrated the ability of a molecular construct comprised of the human (...) leukocyte antigen (HLA)-DRα1 domain linked covalently to mouse (m)MOG-35-55 peptide (DRα1-MOG-35-55 construct) to reduce CNS inflammation and tissue injury in animal models of multiple sclerosis and ischemic stroke. The aim of the current study was to determine if DRα1-MOG-35-55 treatment of a fluid percussion injury (FPI) mouse model of TBI could reduce the lesion size and improve disease outcome measures. Neurodeficits, lesion size, and immune responses were determined to evaluate the therapeutic

Full Text available with Trip Pro

2017 Metabolic brain disease

14. A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-α and TGF-β1 pathways (PubMed)

A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-α and TGF-β1 pathways Renal fibrosis is closely related to chronic inflammation and is under the control of epigenetic regulations. Because the signaling of transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α (TNF-α) play key roles in progression of renal fibrosis, dual blockade of TGF-β1 and TNF-α is desired as its therapeutic approach. Here we screened small molecules showing anti-TNF-α activity (...) in the compound library of indole derivatives. 11 out of 41 indole derivatives inhibited the TNF-α effect. Among them, Mitochonic Acid 35 (MA-35), 5-(3, 5-dimethoxybenzyloxy)-3-indoleacetic acid, showed the potent effect. The anti-TNF-α activity was mediated by inhibiting IκB kinase phosphorylation, which attenuated the LPS/GaIN-induced hepatic inflammation in the mice. Additionally, MA-35 concurrently showed an anti-TGF-β1 effect by inhibiting Smad3 phosphorylation, resulting in the downregulation of TGF-β1

Full Text available with Trip Pro

2017 Scientific reports

15. A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35 (PubMed)

A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35 Organ transplantation remains the most effective treatment for patients with late stage organ failure. Transgenic pigs provide an alternative organ donor source to the limited availability of human organs. However, cellular rejection still remains to be the obstacle for xenotransplantation. Superior to other methods, antigen-specific regulatory T cells (Treg (...) the expected phenotype, CD4+CD25+CD127low/- Foxp3+, and a more activated phenotype. The specificity of PSTreg was demonstrated by suppression of effector T cell (Teff) activation markers of different stages and inhibition of Teff cell proliferation. TolDC and PSTreg exhibited high expression of IL-10 and TGF-β1 at both protein and RNA levels, and PSTreg also highly expressed IL-35 at RNA levels. Upon restimulation, PSTreg retained the activated phenotype and specificity. Taken together, the newly developed

Full Text available with Trip Pro

2017 Scientific reports

16. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. (PubMed)

Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. In the interesting debate entitled "Challenging Views of Alzheimer's Disease II," we defended the position that factors such as oxygen, the single methionine residue of amyloid beta-peptide(1-42) [Abeta(1-42)], and redox metal ions were important for the oxidative stress and neurotoxic properties of this peptide that is critically involved (...) in the pathogenesis of Alzheimer's disease. This brief review summarizes some of our findings relevant to the role of the single methionine residue of Abeta(1-42) in the oxidative stress and neurotoxic properties of this peptide.

2017 Neurobiology of Aging

17. Relative Impact of Complement Receptors CD21/35 (Cr2/1) on Scrapie Pathogenesis in Mice (PubMed)

Relative Impact of Complement Receptors CD21/35 (Cr2/1) on Scrapie Pathogenesis in Mice Complement receptors 1 and 2 (CR1/2 or CD35/CD21) recognize complement-opsonized antigens to initiate innate and adaptive immunity, respectively. CD35 stimulates phagocytosis on macrophages and antigen presentation on follicular dendritic cells (FDCs). CD21 helps activate B cells as part of the B cell coreceptor with CD19 and CD81. Differential splicing of transcripts from the mouse Cr2 gene generates (...) , but rather contact PrPC and coerce it to misfold into more prions, which cause neurodegeneration akin to other protein-misfolding diseases like Alzheimer's disease. A single gene produces two alternatively spliced mRNA transcripts that encode mouse complement receptors CD21/35, which promote efficient prion replication in the lymphoid system and eventual movement to the brain. Here we show that CD21/35 are high-affinity prion receptors, but mice expressing only CD21 die from prion disease sooner than

Full Text available with Trip Pro

2017 mSphere

18. Liver Transplant Survival Index for Patients with Model for End-Stage Liver Disease Score ≥35: Modeling Risk and Adjusting Expectations in the Share 35 Era. (PubMed)

to generate the Liver Transplant Survival Index (LTSI-35), and survival analyses were performed.Five risk groups (very low, low, moderate, high, and severe) were identified, with 1-year graft survival rates of 90.8% ± 0.2%, 89.3% ± 0.3%, 85.0% ± 0.3%, 79.8% ± 0.3%, and 70.3% ± 0.4% (p < 0.001 across groups), respectively. The greatest risk of graft loss was associated with donation after circulatory death (DCD) donors (1-year hazard ratio [HR] = 1.61 [95% CI 1.26 to 2.05], p = 0.001), recipients (...) Liver Transplant Survival Index for Patients with Model for End-Stage Liver Disease Score ≥35: Modeling Risk and Adjusting Expectations in the Share 35 Era. The Share 35 policy for liver allocation prioritizes patients with Model for End-Stage Liver Disease (MELD) scores ≥ 35 for regional sharing of liver allografts. To better assess donor-recipient interactions and inform expectations, this study identified factors affecting graft survival independent of MELD score and derived a risk index

2018 Journal of the American College of Surgeons

19. IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14). (PubMed)

atherosclerosis in the aortas and plasma of ApoE (apolipoprotein E) knockout mice-an atherosclerotic mouse model-and in the plasma of hypercholesterolemic patients. In addition, we found that IL-35 suppresses lysophosphatidylcholine-induced monocyte adhesion to human aortic ECs. Furthermore, our RNA-sequencing analysis shows that IL-35 selectively inhibits lysophosphatidylcholine-induced EC activation-related genes, such as ICAM-1 (intercellular adhesion molecule-1). Mechanistically, using flow cytometry (...) , mass spectrometry, electron spin resonance analyses, and chromatin immunoprecipitation-sequencing analyses, we found that IL-35 blocks lysophosphatidylcholine-induced mitochondrial reactive oxygen species, which are required for the induction of site-specific H3K14 (histone 3 lysine 14) acetylation, increased binding of proinflammatory transcription factor AP-1 in the promoter of ICAM-1, and induction of ICAM-1 transcription in human aortic EC. Finally, IL-35 cytokine therapy suppresses

2018 Thrombosis and Vascular Biology

20. IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB

: 50 participants Observational Model: Case-Control Time Perspective: Cross-Sectional Target Follow-Up Duration: 1 Day Official Title: Regulate Effect of Il-35 Secreting Breg Cells on Tcells and on Diseases Progression in Patients With CHB Actual Study Start Date : July 1, 2017 Estimated Primary Completion Date : April 30, 2019 Estimated Study Completion Date : June 30, 2019 Resource links provided by the National Library of Medicine related topics: (AHRQ) related information: Groups and Cohorts Go (...) IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. IL-35+Breg/Il-35 Effect on T Cell

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>